Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Bright Minds anti-seizure candidate shines in phase 2 win
The New York-based biotech’s serotonin mimic BMB-101 significantly reduced the number of seizures in patients with absence seizures and epilepsies.
Darren Incorvaia
Jan 6, 2026 10:38am
Arrowhead takes aim at obesity with early gene silencing data
Jan 6, 2026 10:19am
Alumis beams as pivotal data on Sotyktu rival drive stock surge
Jan 6, 2026 9:05am
MetaVia weighs in with 9% loss to enter the obesity ring
Jan 5, 2026 10:44am
Zenas stock sinks on autoimmune readout despite hitting endpoint
Jan 5, 2026 9:30am
J&J junks $1.2B eczema therapy while Genmab drops cancer drug
Jan 2, 2026 9:05am